-
公开(公告)号:WO2018078399A1
公开(公告)日:2018-05-03
申请号:PCT/GB2017/053272
申请日:2017-10-31
申请人: IP SCIENCE LIMITED
IPC分类号: A61K9/00 , A61K45/06 , A61K31/01 , A61K31/015 , A61K31/047 , A61K31/065 , A61K31/122 , A61K31/375 , A61K31/6615 , A61L2/00
CPC分类号: A61K31/6615 , A61K9/5123 , A61K31/01 , A61K31/015 , A61K31/047 , A61K31/065 , A61K31/122 , A61K31/375 , A61K45/06 , A61L2/00 , Y02A50/402 , A61K2300/00
摘要: The invention relates to new formulations of carotenoids and chaperone molecules, and relates uses and methods.
摘要翻译: 本发明涉及类胡萝卜素和伴侣分子的新制剂,并涉及用途和方法。 p>
-
公开(公告)号:WO2015162483A1
公开(公告)日:2015-10-29
申请号:PCT/IB2015/000534
申请日:2015-04-21
申请人: TXP PHARMA GMBH
发明人: BOESEN, Thomas
IPC分类号: A61K38/03 , A61K38/22 , C07K14/685
CPC分类号: A61K38/34 , A61K38/03 , C07K14/68 , Y02A50/387 , Y02A50/402 , Y02A50/465 , Y02A50/481
摘要: The present invention provides peptide analogues of a-MSH and γ-MSH, comprising the amino acid sequence of human α-MSH or γ-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
摘要翻译: 本发明提供a-MSH和γ-MSH的肽类似物,其包含人α-MSH或γ-MSH的氨基酸序列或其变体,并且在肽的N末端部分具有支链氨基酸探针 。
-
公开(公告)号:WO2015067713A1
公开(公告)日:2015-05-14
申请号:PCT/EP2014/073967
申请日:2014-11-06
发明人: OTTERLEI, Marit , BACHKE, Siri
CPC分类号: C07K14/00 , A01N25/08 , A01N63/02 , A61K31/165 , A61K31/35 , A61K31/397 , A61K31/43 , A61K31/496 , A61K31/7036 , A61K31/7048 , A61K38/00 , A61K38/14 , A61K38/16 , A61K38/1709 , A61K41/0038 , A61K45/06 , A61L2/10 , A61L2/16 , A61L2202/21 , C07K2319/09 , C07K2319/70 , Y02A50/402 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481
摘要: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 1) and wherein: X 1 is a basic amino acid; X 2 is an aromatic amino acid; X 3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X 4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X 5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents. In other aspects of the invention agents and compositions of the invention may be used in conjunction with one or more additional active agents, such as antibiotics.
摘要翻译: 本发明提供了用于治疗或预防受试者细菌感染的试剂或含有试剂的组合物,其中所述试剂包括:(i)包含PCNA相互作用基序和促进细胞的结构域的寡肽化合物 所述化合物的摄取,其中所述PCNA相互作用基序是X1X2X3X4X5(SEQ ID NO:1),其中:X1是碱性氨基酸; X2是芳香族氨基酸; X3是除芳香族氨基酸,甘氨酸(G)和脯氨酸(P)之外的不带电荷的氨基酸; X4是除脯氨酸(P)以外的任何氨基酸,酸性氨基酸或芳香族氨基酸; X5是碱性氨基酸或脯氨酸(P); 或(ii)包含编码(i)的寡肽化合物的序列的核酸分子。 在某些方面,本发明的试剂和组合物可以用作单一试剂。 在本发明的其它方面,本发明的药剂和组合物可以与一种或多种另外的活性剂如抗生素结合使用。
-
公开(公告)号:WO2015031950A1
公开(公告)日:2015-03-12
申请号:PCT/AU2014/000885
申请日:2014-09-09
CPC分类号: C07K14/195 , A61K8/65 , A61K38/00 , A61K2800/10 , A61Q19/08 , C07K14/78 , Y02A50/402 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481
摘要: The present disclosure relates to recombinant or synthetic collagen-like proteins comprising at least one triple-helical domain and wherein the collagen-like protein is modified compared to a native bacterial collagen-like sequence.
摘要翻译: 本公开涉及包含至少一个三螺旋结构域的重组或合成胶原样蛋白,并且其中胶原样蛋白质与天然细菌胶原样序列相比被修饰。
-
公开(公告)号:WO2014121298A2
公开(公告)日:2014-08-07
申请号:PCT/US2014/014738
申请日:2014-02-04
申请人: SERES HEALTH, INC.
发明人: VON MALTZAHN, Geoffrey , HENN, Matthew, R. , COOK, David, N. , BARRY, David, A. , AFEYAN, Noubar, B. , GOODMAN, Brian , LOMBARDO, Mary-Jane , VULIC, Marin
IPC分类号: A61K39/02
CPC分类号: A61K35/742 , A61K9/0053 , A61K9/48 , A61K9/4816 , A61K35/37 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K45/06 , C12N1/20 , Y02A50/402 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481
摘要: Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore- forming bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.
摘要翻译: 描述了用于填充受试者的胃肠道的方法和组合物。 方法包括向受试者施用治疗组合物,所述治疗组合物包含纯化的孢子形成细菌群体,所述孢子形成细菌通过提供粪便材料并使所述材料经受处理步骤而产生,从而纯化孢子形成细菌。 方法包括施用有效量在胃肠道中接种和/或增加的量,以治疗或预防哺乳动物受试者的生态失调。 p>
-
6.
公开(公告)号:WO2014078801A1
公开(公告)日:2014-05-22
申请号:PCT/US2013/070598
申请日:2013-11-18
IPC分类号: A01N47/44 , A61K31/155 , A01N1/00 , A61P31/04
CPC分类号: A01N47/44 , A61K31/155 , Y02A50/402 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481
摘要: Methods of treating or reducing biofilms, treating a biofilm-related disorder, triggering biofilm disassembly, and preventing biofilm formation using guanidines is described.
摘要翻译: 描述了治疗或减少生物膜,治疗生物膜相关病症,触发生物膜拆卸以及防止使用胍的生物膜形成的方法。
-
7.
公开(公告)号:WO2013113000A2
公开(公告)日:2013-08-01
申请号:PCT/US2013/023451
申请日:2013-01-28
申请人: MONTAGNIER, Luc
发明人: MONTAGNIER, Luc
IPC分类号: C12Q1/68 , C12N1/20 , C12N15/11 , A61K31/7052 , A61K31/65
CPC分类号: C12Q1/703 , A61K31/65 , A61K31/7052 , C12N1/20 , C12N15/11 , C12Q1/689 , Y02A50/402
摘要: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.
摘要翻译: 使用聚合酶链式反应和特异性引物鉴定疾病,病症或病症(例如由人类免疫缺陷病毒引起的那些)的风险因子的方法。 通过组合抗病毒和抗细菌治疗或通过维持或刺激受试者的免疫系统对风险因素进行抗微生物治疗来治疗患有这些疾病,病症或病症的患者的方法。 筛选包括红细胞制剂在内的生物制品的方法。 用于检测与红细胞有关的核酸或微生物试剂的引物和方法,例如在感染HIV并接受抗逆转录病毒疗法的受试者中与红细胞有关的那些试剂。 p>
-
公开(公告)号:WO2012168944A1
公开(公告)日:2012-12-13
申请号:PCT/IN2011/000881
申请日:2011-12-21
申请人: AURIGENE DISCOVERY TECHNOLOGIES LIMITED , SASIKUMAR, Pottayil, Govindan, Nair , RAMACHANDRA, Muralidhara , VADLAMANI, Suresh, Kumar , SHRIMALI, K., Rajeev , SUBBARAO, Krishnaprasad
发明人: SASIKUMAR, Pottayil, Govindan, Nair , RAMACHANDRA, Muralidhara , VADLAMANI, Suresh, Kumar , SHRIMALI, K., Rajeev , SUBBARAO, Krishnaprasad
CPC分类号: C07K7/02 , A61K38/00 , A61K38/08 , C07K5/0227 , Y02A50/385 , Y02A50/401 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/463 , Y02A50/465 , Y02A50/467 , Y02A50/469 , Y02A50/471 , Y02A50/473 , Y02A50/478 , Y02A50/481 , Y02A50/491
摘要: The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
摘要翻译: 本发明提供能够抑制程序性细胞死亡1(PD1)信号传导途径的免疫抑制化合物。 本发明还提供了用于治疗癌症或通过由PD-1,PD-L1或PD-L2诱导的免疫抑制性信号传导引起的免疫增强治疗的感染治疗和使用它们的疗法,作为活性成分的免疫增强底物 。 此外,本发明提供了包含用于癌症,癌症转移,免疫缺陷,感染性疾病等的预防和/或治疗剂的免疫抑制肽化合物或修饰肽部分的药物组合物,以及PD-1或PD-L1作为 测试或诊断剂或这种疾病的研究药物。
-
公开(公告)号:WO2012034955A1
公开(公告)日:2012-03-22
申请号:PCT/EP2011/065701
申请日:2011-09-12
发明人: BOETTGER, Erik , VASELLA, Andrea
IPC分类号: A61K31/70
CPC分类号: A61K31/70 , A61K31/7036 , C07H15/224 , C07H17/04 , Y02A50/402 , Y02A50/481
摘要: The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.
摘要翻译: 本发明涉及人类细菌感染性疾病的新型药理学治疗。 具体地说,本发明涉及式(I)的安普霉素或安普霉素衍生物在人体中治疗细菌感染性疾病的用途。 据证实,阿帕霉素令人惊讶地没有预期的相关氨基糖苷类抗生素观察到的高水平毒性,但实际上甚至比已用于人类药物(如庆大霉素)的化合物显着降低毒性。
-
公开(公告)号:WO2011109119A1
公开(公告)日:2011-09-09
申请号:PCT/US2011/020706
申请日:2011-01-10
申请人: PRESIDENT AND FELLOWS OF HARVARD COLLEGE , LOSICK, Richard , CLARDY, Jon , KOLTER, Roberto , KOLODKIN-GAL, Illana , ROMERO, Diego , CAO, Shugeng
发明人: LOSICK, Richard , CLARDY, Jon , KOLTER, Roberto , KOLODKIN-GAL, Illana , ROMERO, Diego , CAO, Shugeng
CPC分类号: A61K31/198 , A61K31/401 , A61K31/405 , Y02A50/402 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481 , Y10T428/13 , Y10T428/31678 , Y10T428/31989 , Y10T428/31993 , Y10T442/2525 , A61K2300/00
摘要: A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a D-amino acid, said composition being essentially free of the corresponding L-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the D-amino acid is selected from the group consisting of D-alanine, D- cysteine, D-aspartic acid, D-glutamic acid, D-histidine, D-isoleucine, D-lysine, D-leucine, D- asparagine, D-proline, D-glutamine, D-arginine, D-serine, D-threonine, D-valine, D- tryptophan, D-tyrosine, and a combination thereof.
摘要翻译: 一种治疗,减少或抑制细菌生物膜形成的方法,所述方法包括:将制品与包含有效量的D-氨基酸的组合物接触,所述组合物基本上不含相应的L-氨基酸,由此处理 减少或抑制生物膜的形成,其中D-氨基酸选自D-丙氨酸,D-半胱氨酸,D-天冬氨酸,D-谷氨酸,D-组氨酸,D-异亮氨酸,D- 赖氨酸,D-亮氨酸,D-天冬酰胺,D-脯氨酸,D-谷氨酰胺,D-精氨酸,D-丝氨酸,D-苏氨酸,D-缬氨酸,D-色氨酸,D-酪氨酸及其组合。
-
-
-
-
-
-
-
-
-